Previous 10 | Next 10 |
AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the compan...
Plus Therapeutics (NASDAQ:PSTV) said it had expanded its partnership with Medidata, a unit of Dassault Systèmes (OTCPK:DASTY), to speed enrollment and reduce clinical trial costs of its Phase 2 trial of Rhenium-186 NanoLiposome in recurrent glioblastoma. The par...
Companies collaborate to design innovative registrational trial of 186 RNL for recurrent glioblastoma Proprietary Synthetic Control Arm Ⓡ solution intended to enhance enrollment and reduce costs AUSTIN, Texas, April 05, 2022 (GLOBE NEWSWIRE) ...
AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and ...
ReSPECT-LM trial to evaluate safety/tolerability and identify MTD/MFD in three cohorts Rhenium-186 NanoLiposome ( 186 RNL) now in two active U.S. clinical trials for CNS cancers AUSTIN, Texas, March 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasd...
AUSTIN, Texas, March 03, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will sp...
Plus Therapeutics, Inc. (PSTV) Q4 2021 Earnings Conference Call February 24, 2022, 05:00 PM ET Company Participants Marc Hedrick - President & CEO Norman LaFrance - Chief Medical Officer Andrew Sims - CFO Conference Call Participants Jianing Li - Maxim Group Sean Lee - H.C. Wainwright Ed ...
Plus Therapeutics press release (NASDAQ:PSTV): FY GAAP EPS of -$1.11 misses by $0.01. As of December 31, 2021, the Company’s cash balance was $18.4 million, compared to $8.3 million as of December 31, 2020. For further details see: Plus Therapeutics GAAP EPS of -$1.11 misses by $...
Plus Therapeutics (NASDAQ:PSTV) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, after market close. The consensus EPS Estimate is -$0.28 (+84.9% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 do...
Plus Therapeutics (PSTV) is collaborating with Medidata, a unit of Dassault Systèmes (OTCPK:DASTY), to evaluate the use of its Synthetic Control Arm (SCA) solution in a planned phase 2 trial of Rhenium-186 NanoLiposome in recurrent glioblastoma, a type of brain cancer. The...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...